CHEK1 and neoplasm: Although SMIs targeting ATR and CHK1 (M6620 (VX-970) and SRA737) have limited activity in patients as single agents [113,114], they have been shown to trigger innate immune signalling and can be combined with ICB to enhance anti-tumor immune responses in preclinical models and recently in clinical trials [115,116,117].